Chemoprevention of Cancer

Authors

  • Dr. Anne S. Tsao MD,

    1. Tsao is Medical Oncology Fellow, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
    Search for more papers by this author
  • Dr. Edward S. Kim MD,

    1. Kim is Assistant Professor, Director of Educational Programs, Department of Thoracic & Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX
    Search for more papers by this author
  • Dr. Waun Ki Hong MD

    1. Hong is Head, Division of Cancer Medicine, Professor/Chair, Department of Thoracic & Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX
    Search for more papers by this author

Abstract

Cancer chemoprevention is defined as the use of natural, synthetic, or biologic chemical agents to reverse, suppress, or prevent carcinogenic progression to invasive cancer. The success of several recent clinical trials in preventing cancer in high-risk populations suggests that chemoprevention is a rational and appealing strategy. This review will highlight current clinical research in chemoprevention, the biologic effects of chemopreventive agents on epithelial carcinogenesis, and the usefulness of intermediate biomarkers as markers of premalignancy. Selected chemoprevention trials are discussed with a focus on strategies of trial design and clinical outcome. Future directions in the field of chemoprevention will be proposed that are based on recently acquired mechanistic insight into carcinogenesis.

Ancillary